Story perspectives

Engineered Bacteria Target Tumors in Revolutionary Cancer Treatment

2/25/2026

Summary

Story summary

Researchers at the University of Waterloo in Ontario, Canada, are developing cancer treatment using engineered Clostridium sporogenes to consume tumors.
They inserted a gene that lets Clostridium sporogenes tolerate low oxygen, enabling survival near tumor edges.
A quorum-sensing system controls the gene’s activation, so it works only when enough bacteria are present.
The next step tests this engineered bacterium in pre-clinical tumor models to assess targeting potential.

1 of 1

Story summary

Researchers at the University of Waterloo in Ontario, Canada, are developing cancer treatment using engineered Clostridium sporogenes to consume tumors.
They inserted a gene that lets Clostridium sporogenes tolerate low oxygen, enabling survival near tumor edges.
A quorum-sensing system controls the gene’s activation, so it works only when enough bacteria are present.
The next step tests this engineered bacterium in pre-clinical tumor models to assess targeting potential.